Pipeline targeting Respiratory Viruses

Pipeline September 2023

RSV vaccine

The VXB-211 vaccine targets respiratory syncytial virus (RSV), a major cause of severe respiratory disease in young children and elderly.

This candidate vaccine has been shown to induce high level of neutralising antibodies in several preclinical models. It has exceptional production yield and is stable in liquid formulation even at room temperature. 

The VXB-211 vaccine is now progressing into preclinical and development activities with the objective to start a Phase 1 proof-of-concept clinical study during the second half of 2023. 

The ambition is to deliver an RSV vaccine with best-in-class efficacy as a ready-to-use fully liquid formulation. In the future, Vicebio will apply the Molecular Clamp technology to develop multivalent formulations targeting several respiratory viruses into ready-to-use single shot vaccines. 

Metapneumovirus vaccine

Metapneumoviruses are increasingly recognised as additional respiratory viruses of concern causing significant burden of respiratory illness in young children and the elderly.

Discovery and pre-clinical investigations are underway to deliver high quality metapneumovirus F antigen capable of raising protective immunity.

pipeline vaccine image

Influenza vaccine

When applied to influenza A strains, the Molecular Clamp technology has been shown to generate highly stable hemaglutinin antigen which is in “prefusion” conformation and is inducing a potent neutralisation response. Furthermore, upon challenge, vaccinated animals show broader protection than that induced by standard of care.

Additional work is ongoing to evaluate the performance of the technology with influenza B strains.

See McMillan et al : “Development of Molecular Clamp stabilised hemagglutinin vaccines for influenza A viruses”.

SARS-CoV-2 vaccine

A previous version of the Molecular Clamp technology has been successfully used with the spike glycoprotein of the SARS-CoV-2 virus. In a clinical trial conducted in by The University of Queensland with funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the spike antigen stabilised with the Molecular Clamp approach has been shown to induce high levels of neutralisating antibodies superior to convalescent sera both in young and elderly individuals. 

Vaccines targeting other viruses

The Molecular Clamp technology has also been applied to many other viruses including MERS, Ebola, Nipah, Lassa, HTLV-1, CMV and HSV viruses. Protective immunity has been demonstrated for Ebola, MERS, and Nipah in animal challenge models. The broad applicability of the technology in vaccinology is being further evaluated for other indications.